DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT
60-Word AI Digest
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Key Takeaways
- In the second quarter of FY2027, Dr.
- Reddy's Labs experienced a downturn in both revenue and profit.
- However, the company supports new trade margin regulations that aim to improve access to vital medicines.
In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Original Publisher Attribution
This summary was curated from Economic Times.